Skip to main content
Clinical Trials/ACTRN12620000807954
ACTRN12620000807954
Recruiting
未知

REstoring microvascular circulation with Diagnostic Ultrasound and Contrast agEnt (REDUCE): A multicentred, randomised, double blinded, controlled trial in patients presenting with ST elevation myocardial infarction.

niversity of Sydney0 sites150 target enrollmentAugust 11, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
Ischaemic Heart Disease
Sponsor
niversity of Sydney
Enrollment
150
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 11, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Chest Pain with ST segment elevation \>0\.1 mV in two contiguous leads, or ST segment depression \>0\.2mV in two contiguous leads V1\-V3 (consistent with a posterior STEMI)
  • \- Eligible for emergent PCI/antithrombotic/antiplatelet therapy.
  • \- Adequate apical and/or parasternal images by echocardiography.
  • \- No contraindications or hypersensitivities to ultrasound contrast agents.

Exclusion Criteria

  • \- Unable to provide written consent to participate in the trial
  • \- Chest pain lasting \>6 hours
  • \- Cardiogenic shock
  • \- Fibrinolytic therapy prior to arrival in the emergency department
  • \- Life expectancy of less than six months from any other co\-morbidity or terminally ill
  • \- Prior ST\-segment elevation myocardial infarction (STEMI)
  • \- Known or suspected hypersensitivity to perflutren, the contrast agent used for the study
  • \- Known cardiomyopathy
  • \- Known severe valvular heart disease
  • \- Known bleeding diathesis or contraindication to glycoprotein 2b/3a inhibitors, anticoagulants, or aspirin

Outcomes

Primary Outcomes

Not specified

Similar Trials